Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (21-30 of 334) with videos related to

Pageof 34
Sort By:
European Urology|January 22, 2022
Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic TherapyCarole Mercier, Michiel Strijbos, Piet Ost
Urology|September 26, 2017
Editorial CommentFilip Poelaert, Piet Ost, Nicolaas Lumen
Anticancer Research|November 17, 2012
An immobilized antibody targeting N-cadherin facilitates spread of N-cadherin-positive tumour cellsDanielle Maes, Marc Bracke, Piet Ost
European Urology|June 12, 2010
Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30Piet Ost, Alberto Bossi, Gert De Meerleer
European Urology|June 24, 2017
Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3Alison C Tree, Shankar Siva, Piet Ost
Future Oncology (London, England)|October 12, 2017
What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?Ryan Phillips, Piet Ost, Phuoc T Tran
European Urology Oncology|February 18, 2026
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005Alfonso Gomez-Iturriaga, Paul Sargos, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Live to SABR Another Day?Phuoc T Tran, Felix Feng, Piet Ost
European Urology|July 14, 2019
Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265-7Aurélie De Bruycker, Valérie Fonteyne, Piet Ost
Frontiers in Oncology|October 20, 2025
Editorial: The need for pragmatic trials in genitourinary oncologyMieke Van Hemelrijck, Piet Ost, Giorgio Gandaglia
Pageof 34

Showing results (21-30 of 334) with videos related to

Sort By:
Pageof 34
European Urology|January 22, 2022
Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic TherapyCarole Mercier, Michiel Strijbos, Piet Ost
Urology|September 26, 2017
Editorial CommentFilip Poelaert, Piet Ost, Nicolaas Lumen
Anticancer Research|November 17, 2012
An immobilized antibody targeting N-cadherin facilitates spread of N-cadherin-positive tumour cellsDanielle Maes, Marc Bracke, Piet Ost
European Urology|June 12, 2010
Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30Piet Ost, Alberto Bossi, Gert De Meerleer
European Urology|June 24, 2017
Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. "Gotta Catch 'em All" or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1-3Alison C Tree, Shankar Siva, Piet Ost
Future Oncology (London, England)|October 12, 2017
What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?Ryan Phillips, Piet Ost, Phuoc T Tran
European Urology Oncology|February 18, 2026
Re: Riccardo Bertolo, Antonio Luigi Pastore, Paolo Verze, et al. Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.01.005Alfonso Gomez-Iturriaga, Paul Sargos, Piet Ost, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Live to SABR Another Day?Phuoc T Tran, Felix Feng, Piet Ost
European Urology|July 14, 2019
Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265-7Aurélie De Bruycker, Valérie Fonteyne, Piet Ost
Frontiers in Oncology|October 20, 2025
Editorial: The need for pragmatic trials in genitourinary oncologyMieke Van Hemelrijck, Piet Ost, Giorgio Gandaglia
Pageof 34